



## **Charles River Laboratories Appoints Cheri Walker, Ph.D. as Corporate Senior Vice President, Corporate Development**

April 24, 2007

WILMINGTON, Mass.--(BUSINESS WIRE)--April 24, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) announced today the appointment of Cheri Walker, Ph.D. to the role of Corporate Senior Vice President, Corporate Development, effective April 24, 2007. Dr. Walker will be responsible for the Company's global corporate development function, directing all aspects of our merger, acquisition and strategic joint venture activities. She will also participate as an integral member in the strategic planning process of the Company.

Prior to joining Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for QIAGEN Sciences where she oversaw the corporate development of QIAGEN's North American life sciences tools and molecular diagnostics businesses. Previously, Dr. Walker held senior corporate development and operational positions at Invitrogen where she successfully executed acquisition and licensing transactions.

James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories noted, "We are delighted to have Cheri join the Charles River team. Her depth of experience in life science transactions adds greater strength to our management team."

Dr. Walker commented, "I have followed the growth of Charles River for several years and am very excited to be joining a dynamic and expanding company. Corporate Development will play an integral role in this growth and I am looking forward to being part of the team."

Dr. Walker holds a doctorate in Human and Molecular Genetics from Baylor College of Medicine and a bachelor's degree in Biology from Swarthmore College.

### About Charles River Laboratories

Charles River Laboratories based in Wilmington, Massachusetts, partners with global pharmaceutical and biotechnology companies, government agencies and leading academic institutions to advance the drug discovery and development process, bringing drugs to market faster and more efficiently. Charles River's 8,000 employees serve clients worldwide. For more information on Charles River, visit our website at [www.criver.com](http://www.criver.com).

### CONTACT: Investor Contact:

Charles River Laboratories International, Inc.

Susan E. Hardy, 781-262-7616

Corporate Vice President, Investor Relations

or

Media Contact:

Denterlein Worldwide

Diana Pisciotta

[dpisciotta@denterleinworldwide.com](mailto:dpisciotta@denterleinworldwide.com)

SOURCE: Charles River Laboratories International, Inc.